These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 2904648)

  • 21. Dopamine agonist activities of pergolide, its metabolites, and bromocriptine as measured by prolactin inhibition, compulsive turning, and stereotypic behavior.
    Clemens JA; Okimura T; Smalstig EB
    Arzneimittelforschung; 1993 Mar; 43(3):281-6. PubMed ID: 8489554
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serotonergic activation after 2-week intrastriatal infusion of L-dopa and slow recovery of circling in rats with unilateral nigral lesions.
    Kääriäinen TM; García-Horsman JA; Piltonen M; Huotari M; Männistö PT
    Basic Clin Pharmacol Toxicol; 2008 Mar; 102(3):300-7. PubMed ID: 17973898
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effects of chronic levodopa treatment on pre- and postsynaptic markers of dopaminergic function in striatum of parkinsonian monkeys.
    Rioux L; Frohna PA; Joyce JN; Schneider JS
    Mov Disord; 1997 Mar; 12(2):148-58. PubMed ID: 9087972
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The antioxidant drink effective microorganism-X (EM-X) pre-treatment attenuates the loss of nigrostriatal dopaminergic neurons in 6-hydroxydopamine-lesion rat model of Parkinson's disease.
    Datla KP; Bennett RD; Zbarsky V; Ke B; Liang YF; Higa T; Bahorun T; Aruoma OI; Dexter DT
    J Pharm Pharmacol; 2004 May; 56(5):649-54. PubMed ID: 15142343
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CGP 56999A, a GABA(B) receptor antagonist, enhances expression of brain-derived neurotrophic factor and attenuates dopamine depletion in the rat corpus striatum following a 6-hydroxydopamine lesion of the nigrostriatal pathway.
    Enna SJ; Reisman SA; Stanford JA
    Neurosci Lett; 2006 Oct; 406(1-2):102-6. PubMed ID: 16890350
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neurotensin receptors and dopamine transporters: effects of MPTP lesioning and chronic dopaminergic treatments in monkeys.
    Goulet M; Morissette M; Grondin R; Falardeau P; Bédard PJ; Rostène W; Di Paolo T
    Synapse; 1999 Jun; 32(3):153-64. PubMed ID: 10340626
    [TBL] [Abstract][Full Text] [Related]  

  • 27. One-trial conditioned rotation in rats.
    Silverman PB
    NIDA Res Monogr; 1989; 95():540-1. PubMed ID: 2577050
    [No Abstract]   [Full Text] [Related]  

  • 28. Treadmill exercise suppresses nigrostriatal dopaminergic neuronal loss in 6-hydroxydopamine-induced Parkinson's rats.
    Yoon MC; Shin MS; Kim TS; Kim BK; Ko IG; Sung YH; Kim SE; Lee HH; Kim YP; Kim CJ
    Neurosci Lett; 2007 Aug; 423(1):12-7. PubMed ID: 17644250
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dopamine D1 and D2 receptor-mediated acute and long-lasting behavioral effects of glial cell line-derived neurotrophic factor administered into the striatum.
    Kobayashi S; Ogren SO; Hoffer BJ; Olson L
    Exp Neurol; 1998 Dec; 154(2):302-14. PubMed ID: 9878169
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Dermal application of lisuride on parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset and on cases with Parkinson's disease].
    Nomoto M; Iwata S; Irifune M; Kaseda S; Osame M; Fukuda T
    Nihon Shinkei Seishin Yakurigaku Zasshi; 1998 Jun; 18(3):81-7. PubMed ID: 9800199
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intrastriatal infusion of liver growth factor stimulates dopamine terminal sprouting and partially restores motor function in 6-hydroxydopamine-lesioned rats.
    Reimers D; Herranz AS; Díaz-Gil JJ; Lobo MV; Paíno CL; Alonso R; Asensio MJ; Gonzalo-Gobernado R; Bazán E
    J Histochem Cytochem; 2006 Apr; 54(4):457-65. PubMed ID: 16344326
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Stress-induced neurological impairments in an animal model of parkinsonism.
    Snyder AM; Stricker EM; Zigmond MJ
    Ann Neurol; 1985 Nov; 18(5):544-51. PubMed ID: 3935041
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differential interaction of competitive NMDA and AMPA antagonists with selective dopamine D-1 and D-2 agonists in a rat model of Parkinson's disease.
    Löschmann PA; Wüllner U; Heneka MT; Schulz JB; Kunow M; Wachtel H; Klockgether T
    Synapse; 1997 Aug; 26(4):381-91. PubMed ID: 9215597
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nigrostriatal dopaminergic activity, deprenyl treatment, and longevity.
    Knoll J
    Adv Neurol; 1990; 53():425-9. PubMed ID: 2122648
    [No Abstract]   [Full Text] [Related]  

  • 35. The efficacy of levodopa treatment declines in the course of Parkinson's disease: do nondopaminergic lesions play a role?
    Agid Y; Graybiel AM; Ruberg M; Hirsch E; Blin J; Dubois B; Javoy-Agid F
    Adv Neurol; 1990; 53():83-100. PubMed ID: 1978522
    [No Abstract]   [Full Text] [Related]  

  • 36. Dopamine agonist potencies of ergolines.
    Lew JY; Nakamura S; Battista AF; Goldstein M
    Commun Psychopharmacol; 1979; 3(3):179-83. PubMed ID: 115634
    [No Abstract]   [Full Text] [Related]  

  • 37. Subclinical damage to the nigrostriatal dopamine system by MPTP as a model of preclinical Parkinson's disease: a review.
    Burns RS
    Acta Neurol Scand Suppl; 1991; 136():29-36. PubMed ID: 1801534
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Early dopamine agonist therapy in Parkinson's disease.
    Rinne UK
    Mov Disord; 1989; 4 Suppl 1():S86-94. PubMed ID: 2566915
    [No Abstract]   [Full Text] [Related]  

  • 39. Intraventricular infusion of Dopamine in Parkinson's disease.
    Horne MK; Butler EG; Gilligan BS; Wodak J; Stark RJ; Brazenor GA
    Ann Neurol; 1989 Dec; 26(6):792-4. PubMed ID: 2604387
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biochemical and behavioral recovery in a rodent model of Parkinson's disease following stereotactic implantation of dopamine-containing liposomes.
    During MJ; Freese A; Deutch AY; Kibat PG; Sabel BA; Langer R; Roth RH
    Exp Neurol; 1992 Feb; 115(2):193-9. PubMed ID: 1735466
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.